BCG immunotherapy
-
Intravesical instillation of bacillus Calmette–Guérin (BCG) as a treatment for superfcial bladder cancer rarely causes pulmonary complications. While published cases have been pathologically characterized by multiple granulomatous lesions due to disseminated infection, no case presenting as a solitary pulmonary nodule has been reported.
5p vianthony2711 16-04-2021 19 2 Download
-
Pneumonitis is a rare complication of bacillus Calmette-Guerin (BCG) immunotherapy seen in patients with urothelial cancer following the repeated administration of BCG. However, no case of BCG-induced pleurisy has been reported.
4p vimontana2711 05-04-2021 12 2 Download
-
The ever increasing knowledge in the areas of cell biology, the immune system and the mechanisms of cancer are allowing a new phase of immunotherapy to develop. The aim of cancer vaccination is to activate the host immune system and some success has been observed particularly in the use of the BCG vaccine for bladder cancer as an immunostimulant.
10p vinaypyidaw2711 26-08-2020 7 2 Download
-
Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of nonmuscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumorassociated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown.
9p vibaku2711 22-07-2020 2 1 Download
-
To compare the efficacy of low dose (27 mg) Bacillus Calmette-Guérin (BCG) and a full dose (81 mg) BCG immunotherapy for patients with intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) after a typical transurethral bladder resection.
8p vimanila2711 25-06-2020 5 1 Download